Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00

Replimune Group (NASDAQ:REPL) had its price target lifted by JPMorgan Chase & Co. from $16.00 to $18.00 in a report published on Wednesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities research analysts also recently issued reports about the company. Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Replimune Group has a consensus rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Up 0.3 %

Shares of NASDAQ:REPL opened at $12.68 on Wednesday. The company has a market cap of $976.55 million, a P/E ratio of -4.13 and a beta of 1.30. The stock’s 50-day moving average is $12.79 and its 200-day moving average is $11.96. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts predict that Replimune Group will post -2.97 earnings per share for the current year.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares during the period. Geode Capital Management LLC raised its stake in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Barclays PLC raised its stake in shares of Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after acquiring an additional 98,791 shares during the last quarter. LMR Partners LLP raised its stake in shares of Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after acquiring an additional 48,920 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.